Global Bacterial Vaccines for Humans 麻豆原创 Growth 2024-2030

Publication ID:

LPI04246210

Publication Date:

April 15, 2024

Pages:

133

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

A bacterial vaccine is a type of vaccine used to prevent infections caused by bacteria. This type of vaccine works by stimulating the immune system to produce an immune response to a specific bacterium, thereby increasing the body's resistance to that bacterium. Bacterial vaccines usually contain killed or weakened bacteria, their isolated antigens, or their synthesized proteins.
The global Bacterial Vaccines for Humans market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
The 鈥淏acterial Vaccines for Humans Industry Forecast鈥� looks at past sales and reviews total world Bacterial Vaccines for Humans sales in 2023, providing a comprehensive analysis by region and market sector of projected Bacterial Vaccines for Humans sales for 2024 through 2030. With Bacterial Vaccines for Humans sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Bacterial Vaccines for Humans industry.
This Insight Report provides a comprehensive analysis of the global Bacterial Vaccines for Humans landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Bacterial Vaccines for Humans portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Bacterial Vaccines for Humans market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Bacterial Vaccines for Humans and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Bacterial Vaccines for Humans.
United States market for Bacterial Vaccines for Humans is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Bacterial Vaccines for Humans is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Bacterial Vaccines for Humans is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Bacterial Vaccines for Humans players cover Merck, Sanofi, GSK, Mitsubishi Tanabe Pharma and Pfizer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Bacterial Vaccines for Humans market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
Meningococcal Vaccine
Hib Vaccine
BCG Vaccine
Typhoid Vaccine
Anthrax Vaccine
Segmentation by application
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Merck
Sanofi
GSK
Mitsubishi Tanabe Pharma
Pfizer
Bayer
Emergent BioSolutions
Walvax
Chengdu Kanghua Biological Products Co., Ltd.
Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd.
Zhejiang Tianyuan Biopharmaceutical Co., Ltd.
Beijing Institute of Biological Products Co., Ltd.
CanSino Biological Co., Ltd.
Hualan Biological Vaccine Co., Ltd.
Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd.
Key Questions Addressed in this Report
What is the 10-year outlook for the global Bacterial Vaccines for Humans market?
What factors are driving Bacterial Vaccines for Humans market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Bacterial Vaccines for Humans market opportunities vary by end market size?
How does Bacterial Vaccines for Humans break out type, application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Bacterial Vaccines for Humans Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Bacterial Vaccines for Humans by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Bacterial Vaccines for Humans by Country/Region, 2019, 2023 & 2030
2.2 Bacterial Vaccines for Humans Segment by Type
2.2.1 Meningococcal Vaccine
2.2.2 Hib Vaccine
2.2.3 BCG Vaccine
2.2.4 Typhoid Vaccine
2.2.5 Anthrax Vaccine
2.3 Bacterial Vaccines for Humans Sales by Type
2.3.1 Global Bacterial Vaccines for Humans Sales 麻豆原创 Share by Type (2019-2024)
2.3.2 Global Bacterial Vaccines for Humans Revenue and 麻豆原创 Share by Type (2019-2024)
2.3.3 Global Bacterial Vaccines for Humans Sale Price by Type (2019-2024)
2.4 Bacterial Vaccines for Humans Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Bacterial Vaccines for Humans Sales by Application
2.5.1 Global Bacterial Vaccines for Humans Sale 麻豆原创 Share by Application (2019-2024)
2.5.2 Global Bacterial Vaccines for Humans Revenue and 麻豆原创 Share by Application (2019-2024)
2.5.3 Global Bacterial Vaccines for Humans Sale Price by Application (2019-2024)
3 Global Bacterial Vaccines for Humans by Company
3.1 Global Bacterial Vaccines for Humans Breakdown Data by Company
3.1.1 Global Bacterial Vaccines for Humans Annual Sales by Company (2019-2024)
3.1.2 Global Bacterial Vaccines for Humans Sales 麻豆原创 Share by Company (2019-2024)
3.2 Global Bacterial Vaccines for Humans Annual Revenue by Company (2019-2024)
3.2.1 Global Bacterial Vaccines for Humans Revenue by Company (2019-2024)
3.2.2 Global Bacterial Vaccines for Humans Revenue 麻豆原创 Share by Company (2019-2024)
3.3 Global Bacterial Vaccines for Humans Sale Price by Company
3.4 Key Manufacturers Bacterial Vaccines for Humans Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Bacterial Vaccines for Humans Product Location Distribution
3.4.2 Players Bacterial Vaccines for Humans Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Bacterial Vaccines for Humans by Geographic Region
4.1 World Historic Bacterial Vaccines for Humans 麻豆原创 Size by Geographic Region (2019-2024)
4.1.1 Global Bacterial Vaccines for Humans Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Bacterial Vaccines for Humans Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Bacterial Vaccines for Humans 麻豆原创 Size by Country/Region (2019-2024)
4.2.1 Global Bacterial Vaccines for Humans Annual Sales by Country/Region (2019-2024)
4.2.2 Global Bacterial Vaccines for Humans Annual Revenue by Country/Region (2019-2024)
4.3 Americas Bacterial Vaccines for Humans Sales Growth
4.4 APAC Bacterial Vaccines for Humans Sales Growth
4.5 Europe Bacterial Vaccines for Humans Sales Growth
4.6 Middle East & Africa Bacterial Vaccines for Humans Sales Growth
5 Americas
5.1 Americas Bacterial Vaccines for Humans Sales by Country
5.1.1 Americas Bacterial Vaccines for Humans Sales by Country (2019-2024)
5.1.2 Americas Bacterial Vaccines for Humans Revenue by Country (2019-2024)
5.2 Americas Bacterial Vaccines for Humans Sales by Type
5.3 Americas Bacterial Vaccines for Humans Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Bacterial Vaccines for Humans Sales by Region
6.1.1 APAC Bacterial Vaccines for Humans Sales by Region (2019-2024)
6.1.2 APAC Bacterial Vaccines for Humans Revenue by Region (2019-2024)
6.2 APAC Bacterial Vaccines for Humans Sales by Type
6.3 APAC Bacterial Vaccines for Humans Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Bacterial Vaccines for Humans by Country
7.1.1 Europe Bacterial Vaccines for Humans Sales by Country (2019-2024)
7.1.2 Europe Bacterial Vaccines for Humans Revenue by Country (2019-2024)
7.2 Europe Bacterial Vaccines for Humans Sales by Type
7.3 Europe Bacterial Vaccines for Humans Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Bacterial Vaccines for Humans by Country
8.1.1 Middle East & Africa Bacterial Vaccines for Humans Sales by Country (2019-2024)
8.1.2 Middle East & Africa Bacterial Vaccines for Humans Revenue by Country (2019-2024)
8.2 Middle East & Africa Bacterial Vaccines for Humans Sales by Type
8.3 Middle East & Africa Bacterial Vaccines for Humans Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Bacterial Vaccines for Humans
10.3 Manufacturing Process Analysis of Bacterial Vaccines for Humans
10.4 Industry Chain Structure of Bacterial Vaccines for Humans
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Bacterial Vaccines for Humans Distributors
11.3 Bacterial Vaccines for Humans Customer
12 World Forecast Review for Bacterial Vaccines for Humans by Geographic Region
12.1 Global Bacterial Vaccines for Humans 麻豆原创 Size Forecast by Region
12.1.1 Global Bacterial Vaccines for Humans Forecast by Region (2025-2030)
12.1.2 Global Bacterial Vaccines for Humans Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Bacterial Vaccines for Humans Forecast by Type
12.7 Global Bacterial Vaccines for Humans Forecast by Application
13 Key Players Analysis
13.1 Merck
13.1.1 Merck Company Information
13.1.2 Merck Bacterial Vaccines for Humans Product Portfolios and Specifications
13.1.3 Merck Bacterial Vaccines for Humans Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Merck Main Business Overview
13.1.5 Merck Latest Developments
13.2 Sanofi
13.2.1 Sanofi Company Information
13.2.2 Sanofi Bacterial Vaccines for Humans Product Portfolios and Specifications
13.2.3 Sanofi Bacterial Vaccines for Humans Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Sanofi Main Business Overview
13.2.5 Sanofi Latest Developments
13.3 GSK
13.3.1 GSK Company Information
13.3.2 GSK Bacterial Vaccines for Humans Product Portfolios and Specifications
13.3.3 GSK Bacterial Vaccines for Humans Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 GSK Main Business Overview
13.3.5 GSK Latest Developments
13.4 Mitsubishi Tanabe Pharma
13.4.1 Mitsubishi Tanabe Pharma Company Information
13.4.2 Mitsubishi Tanabe Pharma Bacterial Vaccines for Humans Product Portfolios and Specifications
13.4.3 Mitsubishi Tanabe Pharma Bacterial Vaccines for Humans Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Mitsubishi Tanabe Pharma Main Business Overview
13.4.5 Mitsubishi Tanabe Pharma Latest Developments
13.5 Pfizer
13.5.1 Pfizer Company Information
13.5.2 Pfizer Bacterial Vaccines for Humans Product Portfolios and Specifications
13.5.3 Pfizer Bacterial Vaccines for Humans Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Pfizer Main Business Overview
13.5.5 Pfizer Latest Developments
13.6 Bayer
13.6.1 Bayer Company Information
13.6.2 Bayer Bacterial Vaccines for Humans Product Portfolios and Specifications
13.6.3 Bayer Bacterial Vaccines for Humans Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Bayer Main Business Overview
13.6.5 Bayer Latest Developments
13.7 Emergent BioSolutions
13.7.1 Emergent BioSolutions Company Information
13.7.2 Emergent BioSolutions Bacterial Vaccines for Humans Product Portfolios and Specifications
13.7.3 Emergent BioSolutions Bacterial Vaccines for Humans Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Emergent BioSolutions Main Business Overview
13.7.5 Emergent BioSolutions Latest Developments
13.8 Walvax
13.8.1 Walvax Company Information
13.8.2 Walvax Bacterial Vaccines for Humans Product Portfolios and Specifications
13.8.3 Walvax Bacterial Vaccines for Humans Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Walvax Main Business Overview
13.8.5 Walvax Latest Developments
13.9 Chengdu Kanghua Biological Products Co., Ltd.
13.9.1 Chengdu Kanghua Biological Products Co., Ltd. Company Information
13.9.2 Chengdu Kanghua Biological Products Co., Ltd. Bacterial Vaccines for Humans Product Portfolios and Specifications
13.9.3 Chengdu Kanghua Biological Products Co., Ltd. Bacterial Vaccines for Humans Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Chengdu Kanghua Biological Products Co., Ltd. Main Business Overview
13.9.5 Chengdu Kanghua Biological Products Co., Ltd. Latest Developments
13.10 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd.
13.10.1 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Company Information
13.10.2 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Bacterial Vaccines for Humans Product Portfolios and Specifications
13.10.3 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Bacterial Vaccines for Humans Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Main Business Overview
13.10.5 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Latest Developments
13.11 Zhejiang Tianyuan Biopharmaceutical Co., Ltd.
13.11.1 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Company Information
13.11.2 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Bacterial Vaccines for Humans Product Portfolios and Specifications
13.11.3 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Bacterial Vaccines for Humans Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Main Business Overview
13.11.5 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Latest Developments
13.12 Beijing Institute of Biological Products Co., Ltd.
13.12.1 Beijing Institute of Biological Products Co., Ltd. Company Information
13.12.2 Beijing Institute of Biological Products Co., Ltd. Bacterial Vaccines for Humans Product Portfolios and Specifications
13.12.3 Beijing Institute of Biological Products Co., Ltd. Bacterial Vaccines for Humans Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Beijing Institute of Biological Products Co., Ltd. Main Business Overview
13.12.5 Beijing Institute of Biological Products Co., Ltd. Latest Developments
13.13 CanSino Biological Co., Ltd.
13.13.1 CanSino Biological Co., Ltd. Company Information
13.13.2 CanSino Biological Co., Ltd. Bacterial Vaccines for Humans Product Portfolios and Specifications
13.13.3 CanSino Biological Co., Ltd. Bacterial Vaccines for Humans Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 CanSino Biological Co., Ltd. Main Business Overview
13.13.5 CanSino Biological Co., Ltd. Latest Developments
13.14 Hualan Biological Vaccine Co., Ltd.
13.14.1 Hualan Biological Vaccine Co., Ltd. Company Information
13.14.2 Hualan Biological Vaccine Co., Ltd. Bacterial Vaccines for Humans Product Portfolios and Specifications
13.14.3 Hualan Biological Vaccine Co., Ltd. Bacterial Vaccines for Humans Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Hualan Biological Vaccine Co., Ltd. Main Business Overview
13.14.5 Hualan Biological Vaccine Co., Ltd. Latest Developments
13.15 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd.
13.15.1 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Company Information
13.15.2 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Bacterial Vaccines for Humans Product Portfolios and Specifications
13.15.3 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Bacterial Vaccines for Humans Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Main Business Overview
13.15.5 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.